MP84-09 INTERFERENCE WITH GLI BINDING TO ANDROGEN RECEPTORS ALTERS THE AR TRANSCRIPTOME AND EFFECTIVELY INHIBITS ANDROGEN GROWTH-INDEPENDENCE OF PROSTATE CANCER CELLS

Abstract

You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology III1 Apr 2016MP84-09 INTERFERENCE WITH GLI BINDING TO ANDROGEN RECEPTORS ALTERS THE AR TRANSCRIPTOME AND EFFECTIVELY INHIBITS ANDROGEN GROWTH-INDEPENDENCE OF PROSTATE CANCER CELLS Na Li, Sarah Truong, Mannan Nouri, Amy Lubik, Josselin Caradec, and Ralph Buttyan Na LiNa Li More articles by this author , Sarah TruongSarah Truong More articles by this author , Mannan NouriMannan Nouri More articles by this author , Amy LubikAmy Lubik More articles by this author , Josselin CaradecJosselin Caradec More articles by this author , and Ralph ButtyanRalph Buttyan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2233AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Progression to castration resistant prostate cancer (CRPC) is associated with a change in the AR-driven transcriptome away from genes associated with prostate epithelial differentiation towards genes associated with cell survival and mitosis. Previously we showed that Gli proteins bind to the enigmatic N-terminal tau5 transactivation domain of AR and co-activate full-length and truncated ARs. When exogenously overexpressed in androgen growth-dependent LNCaP cells, Gli proteins can elicit androgen growth-independence (AI). Here we show that interference with Gli-AR binding in AI LNCaP variants suppresses the alternate AR transcriptome, restores the AR differentiation transcriptome and suppresses AI growth. METHODS Androgen growth-independent, enzalutamide- (ENZ-) resistant LNCaP cell variants, LNCaP-AI and LN95, were treated with Gli inhibitors (GANT61 and HPI-1) or transfected with Gli3 siRNA or transfected with a small decoy peptide from the Gli2 AR-binding domain (Gli-DP) to disrupt intracellular Gli-AR interactions. RNAs were extracted and expressions of differentiation genes (DGs), PSA and KLK2 or mitotic-regulatory genes (MRGs), UBE2C, CDK1 and CDC20 were measured by real-time qRT-PCR and compared to control-treated (vehicle, non-targeting siRNA or empty vector transfected) cells. Cell growth after Gli manipulation(s) was measured on the Incuyte-Zoom instrument that quantifies real-time cell growth and was compared to control cells. Increasing doses of Enzalutamide (ENZ) were titrated into Gli-DP transfected cells to test whether it cooperates with Gli-AR binding disruption in suppressing AI growth. RESULTS Suppression of global Gli activity, Gli3-specific knockdown and exogenous Gli-DP expression significantly suppressed expressions of MRGs but increased expressions of DGs in both AI cell types. These actions also significantly slowed growth of the cells, with Gli inhibitors and Gli3 knockdown showing complete growth suppression whereas the Gli-DP achieved half-suppression. ENZ treatments further increased growth suppression of the Gli-DP expressing cells. CONCLUSIONS Our results identify the potential for Gli-AR binding interference as a means to control AI/CRPC growth. This interference further cooperates with ENZ to provide very robust growth suppression showing that combined targeting of AR N-terminal and C-terminal domains holds the key for more effective treatments for CRPC. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e1092-e1093 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Na Li More articles by this author Sarah Truong More articles by this author Mannan Nouri More articles by this author Amy Lubik More articles by this author Josselin Caradec More articles by this author Ralph Buttyan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...